Biological activity of N-(4-hydroxyphenyl) retinamide-O-glucuronide in corneal and conjunctival cells of rabbits and humans.
Previous studies of topical retinoic acid for treatment of ocular surface disease met with limited success due to instability and irritancy of the retinoid and lack of efficacy in keratoconjunctivitis sicca. There has, however, been continued interest in the treatment of mucin deficiency and cicatrizing conjunctival diseases, such as ocular cicatricial pemphigoid (OCP), topically with retinoids. In this study the biological activity of stable, water-soluble, synthetic retinoid, N-(4-hydroxyphenyl) retinamide-O-glucuronide (4-HPROG) was investigated in vivo and in vitro using conjunctival and corneal epithelium and fibroblasts. Vitamin A-deficient rabbits with stage 3-4 corneal xerosis and squamous metaplasia confirmed by conjunctival impression cytology were treated with topical 0.1% 4-HPROG in an artificial tear vehicle for 3 weeks. Impression cytology was repeated at 2 and 3 weeks and at 3 weeks conjunctival biopsies were fixed for histology. Growth curves were generated using conjunctival fibroblasts of rabbits and humans (normals and patients with cicatrizing conjunctival disease including OCP and Stevens-Johnson syndrome) cultured in the 10(-8)-10(-6) M 4-HPROG. In vivo, corneal xerosis cleared in three days. A normal conjunctival epithelium was restored by 2 weeks and goblet cells were present by 3 wk, with no change in vehicle-treated controls. No ocular irritation occurred. In vitro, 10(-6) M 4-HPROG inhibits growth of rabbit conjunctival fibroblasts. The retinoid had no effect on proliferation of conjunctival fibroblasts from normal humans but the doubling time of cells from patients with OCP increased significantly, from 50.9 +/- 10.01 h (control) to 61.5 +/- 8.95 h (retinoid). Proliferation of conjunctival fibroblasts from a patient with Stevens-Johnson syndrome was also inhibited. N-(4-hydroxyphenyl) retinamide-O-glucuronide is biologically active and merits further study to determine its efficacy in controlling conjunctival fibrosis and treating ocular surface squamous metaplasia.
Ubels
J L
JL
Department of Ophthalmology, University of Pittsburgh School of Medicine, PA, USA.
Dennis
M H
MH
Mitchell
J H
JH
Wiley
L A
LA
Curley
R W
RW
D000818:Animals; D002455:Cell Division / Q000187:drug effects; D002921:Cicatrix / Q000378:metabolism / Q000473:pathology; D003228:Conjunctiva / Q000166:cytology / Q000378:metabolism* / Q000473:pathology; D003229:Conjunctival Diseases / Q000378:metabolism / Q000473:pathology; D003315:Cornea / Q000166:cytology / Q000378:metabolism* / Q000473:pathology; D005128:Eye Diseases / Q000378:metabolism / Q000473:pathology; D017313:Fenretinide / Q000031:analogs & derivatives* / Q000378:metabolism; D005347:Fibroblasts / Q000166:cytology; D005965:Glucuronates / Q000378:metabolism*; D006801:Humans; D010390:Pemphigoid, Benign Mucous Membrane / Q000378:metabolism / Q000473:pathology; D011817:Rabbits; D017154:Stromal Cells / Q000166:cytology; D014802:Vitamin A Deficiency / Q000378:metabolism / Q000473:pathology
D005965:Glucuronates; C084238:N-((4-hydroxyphenyl)retinamide)-O-glucuronide; D017313:Fenretinide